arrow_back Back to App

Less Animal Testing: Faster Drugs, New Research Methods

This act introduces new rules for the Food and Drug Administration (FDA) aimed at reducing animal testing in drug research. This could speed up the drug approval process, potentially leading to earlier access to innovative therapies for patients. Citizens can expect more efficient drug market entry and improved ethical standards in research.
Key points
Establishes a qualification process for alternative drug testing methods that do not use animals.
Accelerates the approval process for drugs developed using approved, non-animal testing methods.
Increases FDA transparency through regular reports on progress and reductions in animal testing.
Mandates public meetings and guidance issuance to allow public and industry input on new procedures.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 118_HR_7248
Sponsor: Rep. Carter, Earl L. "Buddy" [R-GA-1]
Process start date: 2024-02-06
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

FDA Modernization Act 3.0

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_HR_7248.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2024-02-06.

What are the main provisions?

Key points include:

  • Establishes a qualification process for alternative drug testing methods that do not use animals.
  • Accelerates the approval process for drugs developed using approved, non-animal testing methods.
  • Increases FDA transparency through regular reports on progress and reductions in animal testing.
  • Mandates public meetings and guidance issuance to allow public and industry input on new procedures.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Carter, Earl L. "Buddy" [R-GA-1].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-25.

CATEGORIES

Health